Nemera, world leader in design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generic industries, today announced a collaboration with Noble, the global leader in medical device training solutions, patient onboarding strategies and multisensory product development for the world’s top pharmaceutical brands. This partnership allows Noble to support Nemera’s launch of the new premium add-on passive safety device, Safe'n'Sound® 2.25 ml, by incorporating a robust training platform program in tandem with the drug delivery device. The training solution is designed to replicate the Safe'n'Sound® 2.25 ml in form and function which will allow for better assistance educating patients on the proper use of the device.
As leaders in their respective spaces, Noble and Nemera’s unique alliance will provide a great solution for onboarding and training programs that will strengthen commercial launches and improve patient adherence. As such, Nemera has granted Noble the rights to design, manufacture and distribute training and onboarding devices as well as supporting materials for Nemera. Furthermore, under this agreement, Nemera’s Insight Innovation Center will be a preferred human factors partner for Noble’s Safe’n’Sound® customers. Our ultimate goal is to provide our customers a safe, effective and differentiated combination product.
“We’re excited to partner with Noble and convinced that leveraging each other's expertise adds unparalleled value to our pharmaceutical customers through a combined offering of Nemera’s Safe’n’Sound® with the proven and solid safety device for prefilled syringes with Noble’s leading training solutions which will finally ensure that patients can use our devices safely and effectively. This partnership nicely aligns with our ‘we put patients first’ mission,” said Bernhard Rohn, Nemera’s Strategy and Marketing Vice President.
Recent studies showed 86% of patients who use a self-injection therapy report increased confidence after practicing with a training device that replicates the exact forces, feel and function of the true drug delivery device they use. These statistics demonstrate the need for the types of training devices and other support materials Noble will create through this partnership. 1
Ensuring patient safety and fostering patients’ adherence to therapies are at the heart of everything we do. Our collaboration with Noble further strengthens our capabilities to bringing superior value to patients and customers.
About Noble
Noble is focused on fostering healthy patient outcomes for those who self-administer drug therapies through the development of robust training devices and onboarding solutions for the world’s top pharma brands and biotech companies. Noble manufactures and commercializes training devices that mimic the exact feel, force and function of drug delivery devices such as autoinjectors, prefilled syringes, onbody, nasal and pulmonary devices in order to increase patient adherence and confidence and decrease usage errors. Noble is an Aptar Pharma company, which is part of AptarGroup, Inc. (NYSE:ATR). For more information, visit www.gonoble.com.
About Nemera
Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generics industries. Nemera offers a comprehensive portfolio of products and services across ophthalmology, nasal, inhalation, dermal, transdermal and parenteral delivery. Nemera’s vision is to be the most patient-centric drug delivery device company. Nemera always puts patients first, providing high-quality solutions that have a demonstrable impact on patients’ health. Nemera’s Insight Innovation Center, with offices in North America and Europe, provides consultative services to support your overall device strategy. Providing user research, Human Factors, User Experience design, and Design for manufacturing, our Insight Innovation Center helps customers navigate their device strategy for both novel and platform solutions. Users are at the center of everything that we do in our effort to always put patients first. For more information, visit www.nemera.net.